A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Trial Profile

A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Omacetaxine mepesuccinate (Primary) ; Decitabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Jun 2017 Status changed from active, no longer recruiting to discontinued.
    • 06 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 22 May 2015 Planned primary completion date changed from 1 Aug 2018 to 1 May 2018 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top